全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Metachronous Dermatofibrosarcoma Protuberans (DFSP) and Gastrointestinal Stromal Tumour (GIST): Case Series with Review of Literature

DOI: 10.4236/ss.2026.173010, PP. 95-105

Keywords: Gastrointestinal Stromal Tumour (GIST), Dermatofibrosarcoma Protuberans (DFSP), Imatinib, Metachronous, eGIST, Platelet-Derived Growth Factor (PDGF)

Full-Text   Cite this paper   Add to My Lib

Abstract:

Introduction: The occurrence of metachronous Dermatofibrosarcoma protuberans (DFSP) and Gastrointestinal stromal tumour (GIST) in the same individual is very rare, with few cases reported in the literature. Individually, (DFSP) and (GIST) are slow-growing tumours which are notorious for recurrence, especially if incompletely excised. They are both related to a mutation in the function of platelet-derived growth factor Receptor (PDGFR). We present two cases of metachronous DFSP and GIST, and review the literature. A 60-year-old male presented with a recurrent anterior abdominal wall mass of 2 years’ duration. He had 4 excisions, in 6 years. Histopathologically, the last lesions was diagnosed as DFSP. Five (5) years later, the patient presented with an abdominal mass that was excised and histopathologically reported as Extra Gastrointestinal Stromal Tumour (eGIST). The second patient was a 35-year-old male who had had recurrent excision of a mass at the lower right back, which was histopathologically diagnosed as DFSP. The area was treated with radiotherapy after the surgery. Five (5) years later, he presented with haematemesis and weight loss. A CT scan of the abdomen revealed a large mass closely associated with the stomach. Though initially deemed unresectable, it was later resected because of poor response to targeted therapy with imatinib, with the patient continuing to have persistent severe anaemia and fever. Confirmatory immunohistochemistry (CD117 and DOG-1) was performed in both cases to confirm the diagnosis. Patient number 2, the 35-year-old, only received adjuvant targeted therapy without response. Informed written consent was obtained from the patients, and medical records were obtained from the electronic medical records of the Korle Bu Teaching Hospital. One patient died within 21 days of follow-up, while the other is living without disease 7 months after surgery. CONCLUSION: These two cases highlight the possibility of metachronous occurrence of DFSP and GIST and underscore the need for attending clinicians to maintain a high index of suspicion for this occurrence in patients managed for DFSP.

References

[1]  Wu, C., Tzen, C., Wang, S. and Yeh, C. (2019) Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. Cancers, 11, Article 679.
https://doi.org/10.3390/cancers11050679
[2]  Rutkowski, P., Nowecki, Z.I., Michej, W., Dębiec-Rychter, M., Woźniak, A., Limon, J., et al. (2007) Risk Criteria and Prognostic Factors for Predicting Recurrences after Resection of Primary Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 14, 2018-2027.
https://doi.org/10.1245/s10434-007-9377-9
[3]  Nilsson, B., Bümming, P., Meis‐Kindblom, J.M., Odén, A., Dortok, A., Gustavsson, B., et al. (2005) Gastrointestinal Stromal Tumors: The Incidence, Prevalence, Clinical Course, and Prognostication in the Preimatinib Mesylate Era. Cancer, 103, 821-829.
https://doi.org/10.1002/cncr.20862
[4]  Sasmal, P.K., Sharma, R., Patra, S., Mishra, T.S., Mishra, P. and Rout, B. (2019) Malignant Extra-Gastrointestinal Stromal Tumor of the Mesentery. The Surgery Journal, 5, e65-e68.
https://doi.org/10.1055/s-0039-1693040
[5]  Rutkowski, P. and Hompes, D. (2016) Combined Therapy of Gastrointestinal Stromal Tumors. Surgical Oncology Clinics of North America, 25, 735-759.
https://doi.org/10.1016/j.soc.2016.05.006
[6]  Miettinen, M., Furlong, M., Sarlomo-Rikala, M., Burke, A., Sobin, L.H. and Lasota, J. (2001) Gastrointestinal Stromal Tumors, Intramural Leiomyomas, and Leiomyosarcomas in the Rectum and Anus. The American Journal of Surgical Pathology, 25, 1121-1133.
https://doi.org/10.1097/00000478-200109000-00002
[7]  Karki, B., Munir, M., Parajuli, A., Santhosh, S. and Singh, A. (2024) Gastrointestinal Stromal Tumor (GIST) in a Young Adult: A Rare Presentation and a Multidisciplinary Approach. Cureus, 16, e68001.
https://doi.org/10.7759/cureus.68001
[8]  Ohiaharcbhuaao, B.O. (2025) Clinical Exprience with Gist a Retrospective Analysis. Surgical Gastroenterology and Oncology, 30, Article 144152.
[9]  IJzerman, N.S., Drabbe, C., den Hollander, D., Mohammadi, M., van Boven, H., Desar, I.M.E., et al. (2020) Gastrointestinal Stromal Tumours (GIST) in Young Adult (18-40 Years) Patients: A Report from the Dutch GIST Registry. Cancers, 12, Article 730.
https://doi.org/10.3390/cancers12030730
[10]  McCarthy, C.J., O’Brien, G.C., Cummins, R.J., Kay, E.W. and Broe, P.J. (2010) GIST with a Twist—Upregulation of PDGF-B Resulting in Metachronous Gastrointestinal Stromal Tumor and Dermatofibrosarcoma Protuberans. Journal of Gastrointestinal Surgery, 14, 398-403.
https://doi.org/10.1007/s11605-009-1088-z
[11]  Thway, K., Noujaim, J., Jones, R.L. and Fisher, C. (2016) Dermatofibrosarcoma Protuberans: Pathology, Genetics, and Potential Therapeutic Strategies. Annals of Diagnostic Pathology, 25, 64-71.
https://doi.org/10.1016/j.anndiagpath.2016.09.013
[12]  Ashindoitiang, J.A., Canice Nwagbara, V.I., Ipeh, U.T., Owusu, G.P. and Asuquo, M.E. (2024) Dermatofibrosarcoma Protuberans: Case Series in a Tropical Setting and Review of Literature. Rare Tumors, 16, 1-8.
[13]  Li, Y., Wang, C., Xiang, B., Chen, S., Li, L. and Ji, Y. (2017) Clinical Features, Pathological Findings and Treatment of Recurrent Dermatofibrosarcoma Protuberans. Journal of Cancer, 8, 1319-1323.
https://doi.org/10.7150/jca.17988
[14]  Takahira, T., Oda, Y., Tamiya, S., Higaki, K., Yamamoto, H., Kobayashi, C., et al. (2007) Detection of COL1A1-PDGFB Fusion Transcripts and PDGFB/PDGFRB mRNA Expression in Dermatofibrosarcoma Protuberans. Modern Pathology, 20, 668-675.
https://doi.org/10.1038/modpathol.3800783
[15]  Navarrete-Dechent, C., Mori, S., Barker, C.A., Dickson, M.A. and Nehal, K.S. (2019) Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans. JAMA Dermatology, 155, 361-369.
https://doi.org/10.1001/jamadermatol.2018.4940
[16]  Criscito, M.C., Martires, K.J. and Stein, J.A. (2016) Prognostic Factors, Treatment, and Survival in Dermatofibrosarcoma Protuberans. JAMA Dermatology, 152, 1365-1371.
https://doi.org/10.1001/jamadermatol.2016.1886
[17]  Arellano-Gutiérrez, G., Martínez-Aldrete, L.F., Pérez-Fabián, A. and Maldonado-García, E.L. (2020) Primary Extra-Gastrointestinal Stromal Tumor (EGIST) of the Mesentery: Case Report and Review of Literature. Annals of Medicine and Surgery, 60, 480-483.
https://doi.org/10.1016/j.amsu.2020.11.020
[18]  Joensuu, H., Vehtari, A., Riihimäki, J., Nishida, T., Steigen, S.E., Brabec, P., et al. (2012) Risk of Recurrence of Gastrointestinal Stromal Tumour after Surgery: An Analysis of Pooled Population-Based Cohorts. The Lancet Oncology, 13, 265-274.
https://doi.org/10.1016/s1470-2045(11)70299-6
[19]  Deng, M., Liu, Q., Ren, L., Yuan, W., Xu, C. and Hou, Y. (2024) A Case Report of Abdominal Metastatic Dermatofibrosarcoma Protuberans Misdiagnosed as Gastrointestinal Stromal Tumor. Diagnostic Pathology, 19, Article No. 41.
https://doi.org/10.1186/s13000-023-01430-9

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133